Patents Examined by Robert Landsman
  • Patent number: 10167330
    Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 1, 2019
    Assignee: Emory University
    Inventors: Brantley R. Herrin, Max Dale Cooper, Rudolf Ehrhardt
  • Patent number: 10107794
    Abstract: Co-expression of T1R2 and T1R3 results in a taste receptor that responds to sweet taste stimuli, including naturally occurring and artificial sweeteners. Cells such as U2-OS, which express a functional sweet receptor, can be used in cell-based assays to detect cellular responses to tastants.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: October 23, 2018
    Assignee: PepsiCo, Inc.
    Inventors: Yuliya Kurash, Stephen Gravina
  • Patent number: 10035817
    Abstract: The invention provides processes for preparing purified cell-binding agent cytotoxic agent conjugates comprising subjecting a mixture comprising a cell-binding agent cytotoxic agent conjugate and one or more impurities to a polyvinyl difluoride (PVDF) membrane to remove at least a portion of the impurities from the mixture, thereby providing a purified cell-binding agent cytotoxic agent conjugate.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: July 31, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Xiaoxi Kevin Chen, Xinfang Li
  • Patent number: 10005848
    Abstract: This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: June 26, 2018
    Assignee: GENENTECH, INC.
    Inventors: Jackson G Egen, Jo-Anne Hongo, Steven Kauder, Robert A Lazarus, Lydia Santell, Yan Wu, Meredith Hazen, Wei-Ching Liang
  • Patent number: 9889180
    Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: February 13, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Qiang Yu, Zhen Ning Wee
  • Patent number: 9891211
    Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumor responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumor responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumor responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: February 13, 2018
    Assignee: Gadeta B.V.
    Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
  • Patent number: 9885717
    Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: February 6, 2018
    Assignee: INCYTE CORPORATION
    Inventors: Preeti G. Lal, Y. Tom Tang, Gina A. Gorgone Simone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice K. Au-Young, Henry Yue, Chandra S. Arvizu, Roopa M. Reddy, Jennifer L. Jackson, Olga Bandman
  • Patent number: 9885703
    Abstract: It has been found that a main effect (immunosuppressive activity) of an S1P1 receptor agonist correlates with the selectivity for cells expressing a combination of an S1P1 receptor with G?i2 or G?i3, and that an adverse effect (cardiotoxicity) of an S1P1 receptor agonist correlates with the selectivity for cells expressing a combination of an S1P1 receptor with G?i1.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: February 6, 2018
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Tomohisa Ninomiya, Satoshi Yoshida
  • Patent number: 9884900
    Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides T?RII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: February 6, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • Patent number: 9884915
    Abstract: The present invention relates to antibodies binding specifically to CCR9, and to antigen-binding fragments thereof. It also relates to uses thereof and diagnostic methods using said antibodies.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: February 6, 2018
    Assignee: Consejo Superior de Investigaciones Cientificas C.S.I.C.
    Inventors: Sonia Chamorro Pérez, Ana Franco Villanueva, José Alberto García Sanz, Leonor Kremer Barón, Carlos Martínez Alonso, Maria Vela Cuenca, Laura Carramolino Fitera
  • Patent number: 9878176
    Abstract: Methods, systems and devices are implemented in connection with light-responsive ion channel molecules. One such method is implemented using a light-activated ion channel molecule that responds to a light stimulus. The method includes engineering the light-activated ion channel molecule in a cell; and activating the ion channel molecule, in response to light stimulus that is provided to the ion channel molecule and that has properties that do not activate a ChR2 ion channel, to allow ions to pass through the light-activated ion channel molecule.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: January 30, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Feng Zhang, Viviana Gradinaru
  • Patent number: 9880179
    Abstract: Provided herein are several methods for selecting agents that bind to transmembrane receptors in a conformationally-selective way. In some embodiments, the method may comprise producing: a transmembrane receptor in an active conformation; and said transmembrane receptor in an inactive conformation and using cell sorting to select, from a population of cells comprising a library of cell surface-tethered extracellular capture agents, cells that are specifically bound to either the transmembrane receptor in its active conformation or the transmembrane receptor in its inactive conformation, but not both. In other embodiments, the method may comprise: contacting a GPCR with a population of cells that comprise a library of surface-tethered extracellular proteins; labeling the cell population with a conformationally-specific binding agent, e.g., a G-protein or mimetic thereof; and using cell sorting to select from the cell population cells that bind to the agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: January 30, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Aashish Manglik, Andrew Kruse, Brian Kobilka
  • Patent number: 9872857
    Abstract: The invention encompasses methods of treating a patient with cancer, such as glioblastoma. The methods may include the administration of one or more pharmaceutical compositions that are capable of inhibiting TROY to treat the patient with cancer.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: January 23, 2018
    Assignees: The Translational Genomics Research Institutet, Mayo Foundation for Medical Education and Research
    Inventors: Nhan Tran, Joseph C. Loftus, Harshil Dhruv
  • Patent number: 9873725
    Abstract: The present invention concerns the field of ion channels, and in particular relates to peptides which are suitable for use in the treatment of conditions where the L-type calcium channel (LTCC) density and function is altered. LTCCs are located on the membrane of all excitable cells and control the small voltage gradient across the plasma membrane by allowing the flow of Ca2+ ions down their electrochemical gradient. This Ca2+ flux is critical for numerous processes including cardiac action potential propagation, muscle contraction, Ca2+-dependent gene expression, synaptic efficacy, and cell survival by contributing to various signaling cascades. Reduction of the inward calcium current (ICa) conducted through the LTCCs is seen in several diseases and medications to improve or restores impaired intracellular Ca2+ homeostasis are limited. The present invention reports mimetic peptides (MPs) that through a novel mechanism directly targets LTCCs and, by modulation of LTCC density and function, increases ICa.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: January 23, 2018
    Assignee: CONSIGLIO NAZIONALE DELLE RICHERCHE
    Inventors: Daniele Catalucci, Gianluigi Condorelli
  • Patent number: 9873731
    Abstract: This invention relates to the administration of an animal immunoglobulin source to mammals such as dairy cattle to improve milk production without negatively affecting reproductive parameters.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: January 23, 2018
    Assignee: The Lauridsen Group Incorporated
    Inventors: Francisco Javier Polo Pozo, Joy M. Campbell, Louis E. Russell, Alejandro Bach Ariza
  • Patent number: 9873918
    Abstract: Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: January 23, 2018
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: Ulrich G. Steidl, Laura Barreyro De Pujato, Britta Will, Amit Verma
  • Patent number: 9867777
    Abstract: Disclosed is a liquid formulation which allows long-acting G-CSF conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting G-CSF conjugates.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: January 16, 2018
    Assignee: Hanmi Science Co., Ltd.
    Inventors: Mi Ji Lee, Jae Min Lee, Byung Sun Lee, Sung Min Bae, Se Chang Kwon
  • Patent number: 9868792
    Abstract: Chemerin is a chemoattractant that selectively directs intra-tumor recruitment of CMKLR1+ cells. Blockade of CCRL2 from binding to chemerin in non-neoplastic tumor cells, e.g. peri-tumor stromal and/or hematopoietic cells allows for redistribution of chemerin into the tumor and enhanced responsiveness against a tumor.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 16, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Brian A. Zabel, Eugene C. Butcher, Russell K. Pachynski, Justin Monnier
  • Patent number: 9862762
    Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 9, 2018
    Assignee: MEDIMMUNE, LLC
    Inventors: Partha Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker
  • Patent number: 9862768
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: January 9, 2018
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan